Eye Conditions & Diseases for Current Trials
DIABETIC RETINOPATHY
Glow2 Study
A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) – GLOW2
- Male or female ≥18 years of age
- Type 1 or 2 diabetes mellitus and HbA1c of ≤12%
- Treatment Naïve
- DRSS Levels 47 or 53
The Diamond2 Study
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema
- Male or female adult subject aged 18 to 85 years
- Documented diagnosis of Type 1 or Type 2 diabetes mellitus and an HbA1c of ≤10.0%
- DME with presence of intraretinal and/or subretinal fluid in the study eye
Kyowa Kirin 003 Study
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Diabetic Macular Edema
- Patient must be 18 years of age or older diagnosed with Type-1 or 2 diabetes
- HbA1c ≤ 11%
- Macular thickening SD-OCT secondary to Diabetic Macular Edema
WET MACULAR DEGENERATION
SOL-1 Study
Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
- Are older than 50 years of age
- Have macular choroidal neovascularization due to nAMD who have had visual loss or would be expected to develop visual loss during the course of the study
- Treatment Naïve
Kyowa Kirin 002 Study
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Neovascular Age-Related Macular Degeneration
- Patient must be 50 years of age or older
- Active subfoveal MNV (any subtype) or juxtafoveal MNV secondary to AMD with leakage affecting the fovea
DRY MACULAR DEGENERATION
ReNEW Study
A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (Dry AMD)
- Adults ≥ 55 years of age with at least 1 eye with Dry Macular Degeneration
- Geographic Atrophy in the study eye
We’ll Email You!
If you’d like us to send you more information on these eye conditions and their
clinical trials we’re conducting, just fill out this form.
